Replies to post #2505 on Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[Long-vestor]

Decifer this and maybe you'll understand, there was a complex ownership involved. ..

As more fully described in Item 1.01 above, on October 1, 2007, Genesis Technology Group, Inc., a Florida corporation (“ Genesis ”) executed a Share Acquisition and Exchange Agreement (“ Exchange Agreement ”) by and among
Genesis, Karmoya International Ltd., a British Virgin Islands company (“ Karmoya ”),

and the following shareholders of 100% of Karmoya’s capital stock (the “ Karmoya Shareholders ”):
Wang Shuo,
Ai Yunian,
Zhao Qun,
Chang Zhaozhen,

Cawston Enterprises Ltd., Greenview Capital Advisors LLC,
Cao Wubo,
Xun Guihong,
and Zhang Yihua.

Separately, Karmoya owns 100% of the capital stock of Union Well International Limited, a Cayman Islands company (“ Union Well ”), which has established and owns 100% of the equity in Genesis Jiangbo (Laiyang) Biotech Technologies Co., Ltd., a wholly foreign owned enterprise in the People’s Republic of China (“ GJBT ”).

GJBT has entered into consulting service agreements and equity-related agreements with Laiyang Jiangbo Pharmaceutical Co., Ltd. (“ Laiyang Jiangbo ”), a limited liability company headquartered in, and organized under the laws of, China.

Throughout this Form 8-K, Karmoya, Union Well, GJBT and Laiyang Jiangbo are sometimes collectively referred to as the “LJ Group.”